Biotech Values

[DewDiligence]

As to what this disinformation campaign implies, I agree with you up to a point. It might hurt [Teva’s] credibility a bit if someone calls them on it.

I have a notion of how Teva will worm its way out of this if someone asks about the patent-expiration dates in a public forum. Teva will acknowledge that the patents at issue in the NVS/MNTA case expire in May 2014, and they will say that the Sep 2015 date was meant to refer only to the Mylan case and was not intended to mislead anyone. Since no one on Wall Street cares a whit about the Mylan case, the analysts will accept Teva’s reply at face value and that will be the end of that.

The actual fact of the expirations won't matter for more 3 1/2 years. I think there's a pretty good chance the patents will be overturned long before they expire.

I hope you’re right about that. For now, there’s nothing else to say on this matter.